BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2006

Full document

Business Context and Reporting Period

This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period ending June 23, 2006. The filing addresses a material error discovered regarding the financial statements issued for the quarter ended March 31, 2006, and pro forma information related to a merger with Xcyte Therapies, Inc.

Key Financial Metrics

The filing does not provide current revenue, profit, cash flow, or liquidity metrics. It specifically addresses a correction to balance sheet items:

  • Goodwill: Increase of approximately $825,000.
  • Accrued Liabilities: Increase of approximately $825,000.
  • Merger Purchase Price: Previously incorrectly allocated due to omitted transaction costs.

Material Changes Versus Prior Period

The Company identified an omission of transaction costs incurred by Xcyte Therapies, Inc. during the merger with Cyclacel Group plc. This error resulted in:

  • An understatement of accrued liabilities in the Form 10-Q filed on May 16, 2006.
  • An incorrect allocation of the merger purchase price in the pro forma financial information included in the Form 8-K/A filed on May 27, 2006.

The Company is filing amendments to both the Form 10-Q and the Form 8-K/A to correct these figures.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on future operations, or new risk factors. The primary focus is the non-reliance on previously issued financial statements due to the accounting error. The Company has discussed the matter and the related amendments with its independent accountant.

Investor Verification Checklist

  • Verify the amended Form 10-Q filed to correct the May 16, 2006 filing.
  • Verify the amended Form 8-K/A filed to correct the May 27, 2006 pro forma information.
  • Confirm the $825,000 adjustment to Goodwill and Accrued Liabilities in the updated financial statements.
  • Note the discrepancy between the requested company name (Bio Green Med Solution, Inc.) and the actual registrant (Cyclacel Pharmaceuticals, Inc.).